Sandoz strikes new five-year deal

 Posted 12 February 2024 AM

Sandoz has announced a new five-year partnership with Biocon Biologics for the exclusive rights to promote, sell and distribute biosimilar versions of two top Roche cancer drugs Herceptin and Avastin in Australia.

Under the deal Sandoz will distribute the Biocon brands, Ogivri, a Herceptin biologic and Abvemy, an Avastin biologic, which the company said had previously been distributed by another pharma. According to the ARTG, the sponsor for Ogivri was Maxx Pharma. 

To see the whole article, please login